Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013108" target="_blank" >RIV/00023736:_____/21:00013108 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/21:00075860
Result on the web
<a href="https://doi.org/10.1038/s41375-020-01022-2" target="_blank" >https://doi.org/10.1038/s41375-020-01022-2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-020-01022-2" target="_blank" >10.1038/s41375-020-01022-2</a>

Result language
angličtina
Original language name
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Original language description
Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS). Transfusion dependency in LRMDS patients is associated with inferior outcomes, mainly attributed to severe bone marrow failure. However, iron toxicity, due to frequent RBCT or ineffective erythropoiesis, may be an additional negative prognostic factor. Recently, much progress has been made in unraveling the iron metabolism. The peptide hormone hepcidin is the key regulator by inhibiting iron uptake through degradation of ferroportin, a cellular iron exporter. Erythroferrone and GDF15, produced by erythroblasts, inhibit hepcidin production, which leads to increased uptake and cellular release of iron for the purpose of erythropoiesis.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)